Ashley Toohill
Internal Medicine · Baltimore, MDNPI 1063907848
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,074 and has fallen 97.3% since, to $29 in 2024.
Across 114 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$499
- Novo Nordisk$328
- Lilly USA, LLC$249
- AstraZeneca$164
- Pfizer$150
- Boehringer Ingelheim$145
- plus $689 from 12 others
What the payments were for
- Food & beverage$2,21399%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $499 |
| Novo Nordisk | 18 | $328 |
| Lilly USA, LLC | 12 | $249 |
| AstraZeneca | 10 | $164 |
| Pfizer | 7 | $150 |
| Boehringer Ingelheim | 4 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $118 |
| Novartis | 5 | $108 |
| GSK | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Amgen(2 entities) | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Johnson & Johnson | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $15 |
How this compares
$2,225 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefpodoxime Proxetil | 11 | $470 |
| Ondansetron OdtOndansetron | 11 | $67 |
| Prednisone | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Baltimore
- Param DedhiaBaltimore$636K
- Shawn DhillonBaltimore$227K
- Jeremy SugarmanBaltimore$210K
- Charles FlexnerBaltimore$133K
- Kristen MarroneBaltimore$97K
- Ana-Maria OrbaiBaltimore$89K
- Mark YarchoanBaltimore$89K
- David Muniz PedrogoBaltimore$82K
- Julie PaikBaltimore$76K
- Allison AgwuBaltimore$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.